Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year

Reports Q2 revenue C$107.4M vs. C$95.6M last year. “I am excited to announce that for the first half of 2025, we achieved a record-high adjusted revenues1 of $197 million, a growth of 9% and an adjusted EBITDA of approximately $28 million. Our innovative promoted product portfolio delivered an organic growth of 15% on a constant currency basis during the same period. In addition, we have added over fifty products with the Paladin and Sumitomo transactions. These profitable portfolios included seven pipeline and early launch assets that will further accelerate the growth trajectory of our Canadian business. In addition, we secured a revolving credit facility with NBC ensuring we remain well positioned to continue to transact and execute on our mission to acquire, in-license, develop, and commercialize pharmaceutical products in Latin America and Canada,” said Samira Sakhia, President and CEO of Knight Therapeutics (KHTRF) Inc.